Sign up for our daily briefing
Make your busy days simpler with Axios AM/PM. Catch up on what's new and why it matters in just 5 minutes.
Catch up on coronavirus stories and special reports, curated by Mike Allen everyday
Catch up on coronavirus stories and special reports, curated by Mike Allen everyday
Denver news in your inbox
Catch up on the most important stories affecting your hometown with Axios Denver
Des Moines news in your inbox
Catch up on the most important stories affecting your hometown with Axios Des Moines
Minneapolis-St. Paul news in your inbox
Catch up on the most important stories affecting your hometown with Axios Twin Cities
Tampa Bay news in your inbox
Catch up on the most important stories affecting your hometown with Axios Tampa Bay
Charlotte news in your inbox
Catch up on the most important stories affecting your hometown with Axios Charlotte
(Andrew Harnik / AP)
The Centers for Medicare and Medicaid Services announced today that it has struck a deal with Mylan to reclassify the EpiPen, which will save the Medicaid program hundreds of millions of dollars.
Context: Part of last year's controversy over the price of EpiPens included the device's classification under the Medicaid program. It was classified as a generic rather than a brand name drug, meaning it paid less in rebates to the program.
The agreement: Mylan will reclassify the EpiPen as a brand name drug, which will recalculate the amount it pays to the program in rebates starting retroactively in April 2017.